# A Study to Evaluate the Usability of the SB11 PFS in Subjects With Wet AMD or Macular Oedema Secondary to RVO

> **NCT06176963** · PHASE2 · COMPLETED · sponsor: **Samsung Bioepis Co., Ltd.** · enrollment: 34 (actual)

## Conditions studied

- Neovascular Age-related Macular Degeneration
- Macular Edema
- Retinal Vein Occlusion

## Interventions

- **COMBINATION_PRODUCT:** SB11 PFS

## Key facts

- **NCT ID:** NCT06176963
- **Lead sponsor:** Samsung Bioepis Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-11-21
- **Primary completion:** 2023-11-30
- **Final completion:** 2023-12-12
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2024-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06176963

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06176963, "A Study to Evaluate the Usability of the SB11 PFS in Subjects With Wet AMD or Macular Oedema Secondary to RVO". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06176963. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*